Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able and willing to give written consent to take part in the study voluntarily.
• People aged between 18 and 75 years old (inclusive), of any gender.
• People whose colorectal cancer has spread to other parts of the body (metastatic), confirmed by a laboratory test on a tissue or cell sample.
• People who have not previously had systemic (whole-body) anti-cancer treatment — or, if they received chemotherapy before or after surgery, their cancer did not return or worsen until more than 6 months after that treatment ended.
• People whose general health and ability to carry out daily activities is rated as fully active or restricted only in physically strenuous activity (ECOG score of 0 or 1).
• People whose life expectancy is at least 3 months.
• People who have at least one measurable tumour that has not previously been treated with radiation or other local therapy (unless that tumour has since been confirmed to have grown back or worsened).
• People whose blood and organ function meets the required levels, including acceptable counts for white blood cells, platelets, and haemoglobin; adequate liver, kidney, and clotting function; and sufficient protein levels in the blood — assessed without the use of blood products or growth factor medicines in the 14 days before starting the study.
• Women of childbearing age who have a negative pregnancy test within 72 hours before starting the study, are not breastfeeding, and agree to use effective contraception during the study and for at least 6 months after the last dose.
• Men with partners who could become pregnant who either have had a sterilisation procedure or agree to use effective contraception during the study and for 3 months after the last dose, and agree not to donate sperm during the study period.

Who may not be able to join:

• People who received radiation therapy to a large area of the body within the 4 weeks before starting the study, and who have not yet recovered from side effects of that radiation.
• People with active cancer that has spread to the brain or the lining around the brain (carcinomatous meningitis). People with previously treated and stable brain metastases may still be considered, as long as they have not needed steroid treatment for this for at least 28 days before entering the study — however, carcinomatous meningitis is excluded in all cases.
• People who had major surgery, a large biopsy, or a serious injury within 28 days before starting the study.
• People with a known allergy to anti-angiogenic medicines, components of monoclonal antibody drugs, or the chemotherapy medicines used in the trial (capecitabine, oxaliplatin, or similar platinum-based drugs).
• People with high blood pressure that remains uncontrolled despite taking blood pressure medication (readings at or above 140/90 mmHg).
• People with serious heart conditions, including moderate-to-severe heart failure, unstable chest pain (angina), a heart attack within the past year, or significant irregular heart rhythms that are not well controlled.
• People who have had significant bleeding or a clear tendency to bleed within the 3 months before starting the study (for example, gastrointestinal bleeding, bleeding stomach ulcers, or blood vessel inflammation).
• People who have had a blood clot event within the 6 months before starting the study — such as a stroke, mini-stroke, brain bleed, deep vein thrombosis, or pulmonary embolism (clot in the lungs). Cases of superficial (surface-level) vein clots may be considered at the trial doctor's discretion.
• People currently being treated for another active cancer, except for certain skin cancers or early-stage cervical cancer that have already been fully treated.
• People who, in the opinion of the investigator, have other circumstances that could interfere with their safety or ability to complete the study — such as serious other illnesses (including mental health conditions), significant abnormal lab results, or personal or social factors that could affect their wellbeing or the reliability of trial data.

Important: Always verify eligibility with the trial site directly before applying.